Atherogenic effects of anabolic steroids on serum lipid levels. A literature review.

This article reviews the current body of literature linking anabolic steroids to atherogenic alterations in serum lipid levels. Anabolic steroids cause marked high-density lipoprotein2 levels [corrected] depression (weighted average, 52%) and severe depression of high-density lipoprotein b levels (weighted average, 78%) while raising low-density lipoprotein levels an average of 36%. The mechanism of these lipid changes, their time course in relation to anabolic steroid use, and their dependency on route of anabolic steroid administration are discussed. Interpretation of the observed lipid level changes in light of the epidemiologic data linking lipids to coronary heart disease risk is used to estimate the lipid-based increase in coronary heart disease risk due to anabolic steroid use.

[1]  K. Kashkin,et al.  Hooked on hormones? An anabolic steroid addiction hypothesis. , 1989, JAMA.

[2]  Robert E. Jones,et al.  The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. , 1989, The Journal of clinical endocrinology and metabolism.

[3]  L. Calabrese,et al.  Dietary influences on cardiovascular disease risk in anabolic steroid-using and nonusing bodybuilders. , 1989, Journal of the American College of Nutrition.

[4]  P. Thompson,et al.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. , 1989, JAMA.

[5]  A. Catapano,et al.  Effects of Anabolic Steroids, Testosterone, and HGH on Blood Lipids and Echocardiography Parameters in Body Builders , 1989, International journal of sports medicine.

[6]  T. Beresford,et al.  Anabolic-androgenic steroid dependence. , 1989, The Journal of clinical psychiatry.

[7]  R. Voy,et al.  Anabolic steroid dependence with opioid-type features. , 1988, The New England journal of medicine.

[8]  Király Cl.  Androgenic-anabolic steroid effects on serum and skin surface lipids, on red cells, and on liver enzymes. , 1988 .

[9]  Veneri Rj,et al.  Anabolic steroid-induced cholestasis: choleretic response to corticosteroids. , 1988 .

[10]  R. Mcnutt,et al.  Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. , 1988, The American journal of cardiology.

[11]  D. Katz,et al.  Affective and psychotic symptoms associated with anabolic steroid use. , 1988, The American journal of psychiatry.

[12]  D. Evans,et al.  Hepatic tumours induced by anabolic steroids in an athlete. , 1988, Journal of clinical pathology.

[13]  P. Demacker,et al.  Deleterious Effects of Anabolic Steroids on Serum Lipoproteins, Blood Pressure, and Liver Function in Amateur Body Builders , 1988, International journal of sports medicine.

[14]  Krauss Rm,et al.  Lipoprotein subspecies and risk of coronary disease. , 1988 .

[15]  L. Fried,et al.  Cholesterol, lipoproteins, and coronary heart disease in women. , 1988, Clinical chemistry.

[16]  G. McKillop,et al.  Lipoprotein analysis in bodybuilders. , 1987, International journal of cardiology.

[17]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[18]  W. Hazzard,et al.  The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. , 1987, Metabolism: clinical and experimental.

[19]  R. Mb,et al.  Adverse effects of anabolic steroids in athletes. , 1987 .

[20]  K. Ishak,et al.  Hepatotoxic Effects of the Anabolic/Androgenic Steroids1 , 1987, Seminars in liver disease.

[21]  M. Alen,et al.  Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes , 1987, The American journal of sports medicine.

[22]  J. Cohen,et al.  Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. , 1987, The Journal of clinical endocrinology and metabolism.

[23]  N. Miller.  Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.

[24]  I. Godsland,et al.  Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol). , 1986, Clinical science.

[25]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[26]  J. Strong.  Landmark perspective: Coronary atherosclerosis in soldiers. A clue to the natural history of atherosclerosis in the young. , 1986, JAMA.

[27]  J. Roberts,et al.  ADENOCARCINOMA OF PROSTATE IN 40-YEAR-OLD BODY-BUILDER , 1986, The Lancet.

[28]  J. Burrin,et al.  Severe hyperglucagonaemia during treatment with oxymetholone. , 1986, British medical journal.

[29]  T. Noakes,et al.  Altered Serum Lipoprotein Profiles in Male and Female Power Lifters Ingesting Anabolic Steroids. , 1986, The Physician and sportsmedicine.

[30]  R. Levy.  Cholesterol and coronary artery disease. What do clinicians do now? , 1986, The American journal of medicine.

[31]  Gerald S. Berenson,et al.  Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa heart study , 1986 .

[32]  H. Kopera.  The history of anabolic steroids and a review of clinical experience with anabolic steroids. , 1985, Acta endocrinologica. Supplementum.

[33]  R. Stout.  Overview of the association between insulin and atherosclerosis. , 1985, Metabolism: clinical and experimental.

[34]  C. Glueck.  Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. , 1985, American heart journal.

[35]  P. Thompson,et al.  Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. , 1985, Medicine and science in sports and exercise.

[36]  M. Levitt,et al.  Anabolic steroids and colonic cancer , 1985, The Medical journal of Australia.

[37]  R. Hanson,et al.  Home management of asthma , 1985, The Medical journal of Australia.

[38]  M. Alen,et al.  Reduced High-Density Lipoprotein-Cholesterol in Power Athletes: Use of Male Sex Hormone Derivates, an Atherogenic Factor , 1984, International journal of sports medicine.

[39]  G. Rovere,et al.  Anabolic steroids: A review of the literature , 2009 .

[40]  C. Glueck,et al.  Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. , 1984, Metabolism: clinical and experimental.

[41]  W. Hazzard,et al.  Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. , 1984, Biochimica et biophysica acta.

[42]  A. Surabote.  The effect of orally administered androgens on sperm count and sperm motility. , 1984, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[43]  A. Goldberg,et al.  High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. , 1984, JAMA.

[44]  D. Costill,et al.  Anabolic Steroid Use Among Athletes: Changes in HDL-C Levels , 1984 .

[45]  T. Fahey,et al.  HDL-C in Five Elite Athletes Using Anabolic-Androgenic Steroids , 1984 .

[46]  E. Nieschlag,et al.  REVERSIBLE AZOOSPERMIA INDUCED BY THE ANABOLIC STEROID 19-NORTESTOSTERONE , 1984, The Lancet.

[47]  S. Kelsey,et al.  The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[48]  U. Singh,et al.  Androgens and hepatocellular carcinoma in an athlete. , 1984, Annals of internal medicine.

[49]  T. Moore,et al.  Adenosquamous carcinoma of the lung and the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[50]  D. Zevin,et al.  Hepatic lesions in patients on anabolic androgenic therapy. , 1983, Israel journal of medical sciences.

[51]  S. Haffner,et al.  Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. , 1983, Metabolism: clinical and experimental.

[52]  W. Hazzard,et al.  Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. , 1982, Metabolism: clinical and experimental.

[53]  D. Ballantyne,et al.  High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. , 1982, Metabolism: clinical and experimental.

[54]  A. Kitabchi,et al.  Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. , 1981, The Journal of clinical endocrinology and metabolism.

[55]  E. Nikkilä,et al.  Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. , 1980, Atherosclerosis.

[56]  S. Sasayama,et al.  Contractile Performance of the Hypertrophied Ventricle in Patients with Systemic Hypertension , 1980, Circulation.

[57]  P. Wahl,et al.  High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. , 1980, Atherosclerosis.

[58]  K. Pyörälä.  Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland , 1979, Diabetes Care.

[59]  T. Welborn,et al.  Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations , 1979, Diabetes Care.

[60]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[61]  S B Hulley,et al.  HDL Cholesterol and Other Lipids in Coronary Heart Disease: The Cooperative Lipoprotein Phenotyping Study , 1977, Circulation.

[62]  A. Goldberg,et al.  Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. , 1977, The Journal of clinical investigation.

[63]  P. Holma.  Effects of an anabolic steroid (metandienone) on spermatogenesis. , 1977, Contraception.

[64]  H. Adlercreutz,et al.  Effect of an anabolic steroid (metandienon) on plasma LH-FSH, and testosterone and on the response to intravenous administration of LRH. , 1976, Acta endocrinologica.

[65]  J. Huttunen,et al.  Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase A1 of human postheparin plasma. , 1975, The New England journal of medicine.

[66]  S. Strømme,et al.  Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males. , 1974, Medicine and science in sports.

[67]  V. Wynn,et al.  THE EFFECT OF ANABOLIC STEROIDS ON BLOOD SUGAR AND PLASMA INSULIN LEVELS IN MAN. , 1963, Metabolism: clinical and experimental.